Regenxbio Inc (STU:RB0)
€ 9.45 0.1 (1.07%) Market Cap: 469.56 Mil Enterprise Value: 307.28 Mil PE Ratio: 0 PB Ratio: 1.65 GF Score: 65/100

Regenxbio Inc at Barclays Virtual Gene Editing & Therapy Summit Transcript

May 24, 2023 / 01:15PM GMT
Release Date Price: €18 (-3.23%)
Huidong Wang
Barclays Bank PLC, Research Division - Research Analyst

Good morning, everyone. My name is Gena Wang, and I'm a SMID Cap biotech analyst at Barclays. Welcome to our seventh Gene Editing & Gene Therapy Summit. It is really nice to have this event happen again. I would like to thank all the participants, investors, companies and especially our event team and corporate access team who made this event possible. And with that, I would like to introduce our next presenter, Ken Mills, President and the Chief Executive Officer of REGENXBIO. Ken, thank you very much for joining us today.

Kenneth T. Mills
REGENXBIO Inc. - President, CEO & Director

Good morning, Gena. Thanks for having us.

Questions & Answers

Huidong Wang
Barclays Bank PLC, Research Division - Research Analyst

Okay. So I think we will start with -- can you hear me? Okay. We will start with, say, the DMD program, your DMD gene therapy program. So maybe start with like now given the evolving dynamic of the DMD gene therapy space

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot